Cargando…

SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments

INTRODUCTION: The study aims to evaluate the concentration of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike1 protein (S1RBD) in BNT162b2- vaccinated relapsing-remitting multiple sclerosis (RRMS) individuals receiving disease-modifying treatments (DMTs). METHODS: Serum fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambrianides, Anastasia, Deeba, Elie, Hadjiagapiou, Maria, Pantzaris, Marios, Krashias, George, Christodoulou, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998932/ https://www.ncbi.nlm.nih.gov/pubmed/36908621 http://dx.doi.org/10.3389/fneur.2023.1092999

Ejemplares similares

A Preclinical Investigation on the Role of IgG Antibodies against Coagulant Components in Multiple Sclerosis
por: Hadjiagapiou, Maria S., et al.
Publicado: (2023)

Genetic Markers for Thrombophilia and Cardiovascular Disease Associated with Multiple Sclerosis
por: Hadjiagapiou, Maria S., et al.
Publicado: (2022)

The expression profile of virus-recognizing toll-like receptors in natural killer cells of Cypriot multiple sclerosis patients
por: Deeba, Elie, et al.
Publicado: (2020)

Serum Reactive Antibodies against the N-Methyl-D-Aspartate Receptor NR2 Subunit—Could They Act as Potential Biomarkers?
por: Hadjiagapiou, Maria S., et al.
Publicado: (2023)

SARS CoV- 2 vaccination induces antibodies against cardiolipin
por: Krashias, George, et al.
Publicado: (2022)

Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca
por: Deeba, Elie, et al.
Publicado: (2022)

A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
por: Pafiti, Anna, et al.
Publicado: (2023)

Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
por: Krashias, George, et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature
por: Lambrianides, Sakis, et al.
Publicado: (2018)

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients
por: Pitzalis, Maristella, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective
por: Jatoi, Hafsa Nazir, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
por: Rico, Audrey, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Long-term memory CD8(+) T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine
por: Kuse, Nozomi, et al.
Publicado: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
por: Li, Tingting, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
por: Goupil, Rémi, et al.
Publicado: (2021)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
por: Athanasiou, Nikolaos K., et al.
Publicado: (2023)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sqcu1r2hj8n5jq9qsk29pguch4